Advanced Ophthalmic Drug Delivery Systems and AI-Assisted Drug Discovery: Current Progress and Future Perspectives

Abstract

Ophthalmic drug development remains one of the most challenging areas in pharmaceutical research due
to the complex anatomy and protective barriers of the eye. Conventional ocular dosage forms, particularly
topical formulations, often exhibit poor bioavailability because of rapid tear turnover, blinking, nasolacrimal
drainage, and limited corneal permeability. These limitations reduce therapeutic efficiency and necessitate
frequent dosing, ultimately affecting patient compliance. In recent years, significant advances have been

achieved in the development of innovative ocular drug delivery systems, including ocular implants, hydro-
gels, nanoparticles, nanomicelles, liposomes, microneedles, iontophoresis, in situ gels, and drug-eluting

contact lenses. These technologies aim to improve drug retention, enhance tissue penetration, and provide
sustained therapeutic effects for both anterior and posterior segment eye diseases. Simultaneously, artificial
intelligence (AI) and digital technologies are transforming ophthalmic drug discovery and development

by accelerating target identification, molecular screening, biomarker analysis, and formulation optimiza-
tion. AI-driven approaches such as machine learning, deep learning, explainable AI, and large language

models have shown considerable potential in reducing development timelines and improving predictive

accuracy. In addition, additive manufacturing technologies, including three-dimensional printing and hot-
melt extrusion, have enabled the development of personalized ophthalmic devices and customized drug

delivery systems. Despite these advances, several challenges remain, including manufacturing complexity,
regulatory uncertainties, scalability issues, data privacy concerns, and the absence of harmonized global
guidelines for AI-assisted therapeutics. This review highlights recent developments in advanced ocular drug
delivery systems, emerging AI-based technologies, regulatory perspectives, and future opportunities aimed
at improving the treatment of complex ocular diseases and reducing the global burden of visual impairment.